Volume 16, Issue 5 pp. 1021-1029
Full Access

Structural requirements for the glycolipid receptor of human uropathogenic Escherichia coli

Robert Striker

Robert Striker

Department of Molecular Microbiology, Box 8230, Washington University, School of Medicine, St. Louis, Missouri 63110, USA.

Search for more papers by this author
Ulf Nilsson

Ulf Nilsson

Organic Chemistry 2, Chemical Centre, The Lund Institute of Technology, University of Lund, PO Box 124, S-221 00 Lund, Sweden.

Search for more papers by this author
Andrea Stonecipher

Andrea Stonecipher

Department of Molecular Microbiology, Box 8230, Washington University, School of Medicine, St. Louis, Missouri 63110, USA.

Search for more papers by this author
Göran Magnusson

Göran Magnusson

Organic Chemistry 2, Chemical Centre, The Lund Institute of Technology, University of Lund, PO Box 124, S-221 00 Lund, Sweden.

Search for more papers by this author
Scott J. Hultgren

Corresponding Author

Scott J. Hultgren

Department of Molecular Microbiology, Box 8230, Washington University, School of Medicine, St. Louis, Missouri 63110, USA.

*For correspondence. Tel. (314)362 6772; Fax (314) 362 1998.Search for more papers by this author
First published: June 1995
Citations: 57

Summary

The binding of uropathogenic Escherichia coli to the globo series of glycolipids via P pili is a critical step in the infectious process that is mediated by a human-specific PapG adhesin. Three classes of PapG adhesins exist with different binding specificities to Galα4Gal-containing glycolipids. The structural basis for PapG recognition of the human glycolipid receptor globoside was investigated by using soluble saccharide analogues as inhibitors of bacterial haemagglutination. The minimum binding epitope was confirmed as the Galα4Gal moiety, but parts of the GalNAcβ and glucose residues, which flank the Galα4Gal in globoside (GbO4), were also shown to be important for strong binding. Furthermore, the same five hydroxyl groups of Galα4Gal in globotriasyl ceramide that were recognized by a previously characterized PapG variant were also recognized by the human-specific PapG in binding the GbO4 that dominates In the human kidney. Saccharide analogues that blocked haemagglutination also blocked the adherence of human uropathogenic E. coli to human kidney sections. Knowledge of the molecular details of the PapG-GbO4 interaction will make it possible to design antiadherence therapeutics.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.